These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 32056038

  • 1. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
    Li K, Tang M, Tong S, Wang C, Sun Q, Lv M, Sun X, Wang T, Jin S.
    Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
    [Abstract] [Full Text] [Related]

  • 2. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.
    Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lässer C, Gho YS, Hill AF, Nilsson JA, Lötvall J.
    Proc Natl Acad Sci U S A; 2017 Jul 18; 114(29):E5930-E5939. PubMed ID: 28684402
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
    Kozar I, Cesi G, Margue C, Philippidou D, Kreis S.
    Biochim Biophys Acta Gen Subj; 2017 Nov 18; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.
    Corre S, Tardif N, Mouchet N, Leclair HM, Boussemart L, Gautron A, Bachelot L, Perrot A, Soshilov A, Rogiers A, Rambow F, Dumontet E, Tarte K, Bessede A, Guillemin GJ, Marine JC, Denison MS, Gilot D, Galibert MD.
    Nat Commun; 2018 Nov 14; 9(1):4775. PubMed ID: 30429474
    [Abstract] [Full Text] [Related]

  • 11. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
    Marusak C, Thakur V, Li Y, Freitas JT, Zmina PM, Thakur VS, Chang M, Gao M, Tan J, Xiao M, Lu Y, Mills GB, Flaherty K, Frederick DT, Miao B, Sullivan RJ, Moll T, Boland GM, Herlyn M, Zhang G, Bedogni B.
    Clin Cancer Res; 2020 Nov 15; 26(22):6039-6050. PubMed ID: 32820016
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
    Vergani E, Dugo M, Cossa M, Frigerio S, Di Guardo L, Gallino G, Mattavelli I, Vergani B, Lalli L, Tamborini E, Valeri B, Gargiuli C, Shahaj E, Ferrarini M, Ferrero E, Gomez Lira M, Huber V, Del Vecchio M, Sensi M, Leone BE, Santinami M, Rivoltini L, Rodolfo M, Vallacchi V.
    Cell Commun Signal; 2020 Sep 23; 18(1):156. PubMed ID: 32967672
    [Abstract] [Full Text] [Related]

  • 14. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.
    Jandova J, Wondrak GT.
    J Invest Dermatol; 2022 May 23; 142(5):1456-1465.e1. PubMed ID: 34687745
    [Abstract] [Full Text] [Related]

  • 15. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.
    Hassel JC, Buder-Bakhaya K, Bender C, Zimmer L, Weide B, Loquai C, Ugurel S, Slynko A, Gutzmer R, German Dermatooncology Group (DeCOG/ADO).
    Cancer Med; 2018 Jan 23; 7(1):95-104. PubMed ID: 29266761
    [Abstract] [Full Text] [Related]

  • 16. miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.
    Nguyen MT, Lin CH, Liu SM, Miyashita A, Ihn H, Lin H, Ng CH, Tsai JC, Chen MH, Tsai MS, Lin IY, Liu SC, Li LY, Fukushima S, Lu J, Ma N.
    Neoplasia; 2020 Dec 23; 22(12):789-799. PubMed ID: 33142243
    [Abstract] [Full Text] [Related]

  • 17. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
    Guo S, Yue Q, Wang S, Wang H, Ye Z, Zhang W, Shi Q, Gao T, Li C, Zhu G.
    J Dermatol Sci; 2023 Feb 23; 109(2):52-60. PubMed ID: 36858850
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S, Amaro A, Levati L, Alvino E, Lacal PM, Mastroeni S, Ruffini F, Bonmassar L, Antonini Cappellini GC, Felli N, Carè A, Pfeffer U, D'Atri S.
    J Exp Clin Cancer Res; 2019 Jun 21; 38(1):272. PubMed ID: 31227006
    [Abstract] [Full Text] [Related]

  • 20. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC, Stiff AR, Bainazar M, Regan K, Olaverria Salavaggione GN, Maharry S, Blachly JS, Krischak M, Walker CJ, Latchana N, Tridandapani S, de la Chapelle A, Eisfeld AK, Carson WE.
    Proc Natl Acad Sci U S A; 2017 Sep 05; 114(36):9629-9634. PubMed ID: 28827320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.